10-Q/A: Allurion Restates Q3 2024 Financials, Workforce Cut 50%

Allurion Technologies, Inc. filed an amended quarterly report for Q3 2024, restating financials due to accounting errors and announcing a significant workforce reduction.

Summary

• Allurion Technologies, Inc. (ALUR) filed an Amendment No. 1 to its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, restating previously issued unaudited condensed consolidated financial statements.
• The restatement was due to an error identified in historical consolidated financial statements from Q4 2023 to Q1 2025, causing overstatements and understatements in comprehensive income/loss, net income/loss, and accumulated deficit.
• The error had no impact on revenue, gross profit, operating expenses, operating profit/loss, or cash and cash equivalents.
• A 1-to-25 reverse stock split was effected on January 3, 2025, and retrospectively adjusted in the financial statements.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, due to existing material weaknesses in internal control over financial reporting.
• The company's revenue decreased by 71% to $5.4 million for the three months ended September 30, 2024, and by 41% to $26.5 million for the nine months ended September 30, 2024, compared to the same periods in 2023.
• Net income (restated) was $8.7 million for Q3 2024 and $2.4 million for the nine months ended September 30, 2024, primarily driven by non-operational fair value adjustments.
• The French regulatory authority (ANSM) suspended sales of the Allurion Balloon in France on August 6, 2024, leading to a $1.2 million reduction in Q3 2024 revenue from customer returns.
• Allurion received notices from the NYSE in August 2024 for non-compliance with minimum share price ($1.00) and minimum market capitalization ($50.0 million) listing standards.
• The Board approved a restructuring plan on November 6, 2024, to reduce the workforce by approximately 113 roles (50%), with estimated one-time charges of $3.5 million in Q4 2024.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date.

Sentiment

Score: 2

Explanation: The company faces severe operational and financial challenges, including a substantial revenue decline, regulatory suspension of its key product in a major market, and non-compliance with NYSE listing standards. The 'going concern' warning and 50% workforce reduction underscore the critical situation, overshadowing the accounting-driven net income improvement.

Positives

• Restated net income of $8.7 million for the three months ended September 30, 2024, compared to a net loss of $21.6 million in the prior year, primarily due to non-operational fair value adjustments.
• Restated net income of $2.4 million for the nine months ended September 30, 2024, compared to a net loss of $61.4 million in the prior year, primarily due to non-operational fair value adjustments.
• Operating expenses saw substantial reductions: Sales and marketing decreased by $8.8 million (63%) for Q3 2024, R&D by $4.0 million (55%), and General and Administrative by $11.9 million (63%).
• The AUDACITY clinical trial is nearing completion, with the last patient treated in September 2024, potentially paving the way for FDA submission.
• Successfully raised capital through convertible notes ($48.0 million), a public offering ($15.2 million net), a private placement ($2.5 million net), and an equity line financing ($0.4 million).
• The company is currently in compliance with financial covenants under the Amended Note Purchase Agreement as of September 30, 2024.

Negatives

• Revenue plummeted by 71% to $5.4 million for the three months ended September 30, 2024, and 41% to $26.5 million for the nine months ended September 30, 2024, primarily due to decreased unit sales and distributor inventory adjustments.
• Gross profit declined sharply by 78% to $3.1 million for the three months ended September 30, 2024, and 46% to $19.0 million for the nine months ended September 30, 2024.
• The French regulatory authority (ANSM) suspended sales of the Allurion Balloon in France, resulting in a $1.2 million reduction in Q3 2024 revenue from customer returns.
• Received notices from the NYSE for non-compliance with both the minimum average closing share price ($1.00) and minimum market capitalization ($50.0 million) requirements, indicating a high risk of delisting.
• Management has concluded there is 'substantial doubt about its ability to continue as a going concern' for the next year.
• Identified material weaknesses in internal control over financial reporting, leading to the restatement of previously issued financial statements.
• Approved a restructuring plan on November 6, 2024, involving a reduction of approximately 113 roles (50% of the workforce), with estimated one-time charges of $3.5 million.
• Expects to continue incurring net losses and negative operating cash flows for the foreseeable future.

Risks

• Inability to achieve and maintain profitability, as the business is highly dependent on the commercial success of the Allurion Balloon.
• Failure to gain broader market acceptance of current and future products, potentially leading to sales below expectations.
• Inability to successfully implement remediation programs to resume sales of the Allurion Balloon in France or any other country that suspends sales.
• Negative effect of market withdrawal in one country on regulatory approval processes and commercialization ability in other countries.
• Failure to obtain or maintain regulatory approvals or clearances in the United States and other international jurisdictions.
• Risks associated with preclinical studies and clinical trials, including negative or inconclusive results, delays, increased costs, and regulatory non-compliance.
• Negative publicity, product defects, and litigation concerning products could harm reputation and reduce demand.
• Adverse events or undesirable side effects caused by the Allurion Balloon could lead to regulatory withdrawal or modification of approvals, restrictive labeling, or product recalls.
• Risk of NYSE delisting due to non-compliance with minimum share price and market capitalization requirements, which would reduce liquidity and market price of common stock.
• Significant amount of debt ($48.0 million in RTW Convertible Notes and royalty obligations) may affect the ability to operate the business and secure additional financing, with a risk of default on financial covenants.
• Vulnerability to downturns in business, industry, or the economy due to debt covenants and collateralized assets.
• Rapid evolution of technology and treatment options within the industry may cause consumers to delay purchases.
• Dependence on third-party suppliers and logistics providers, with potential for supply chain disruptions.
• Exposure to foreign currency exchange risk due to international operations.
• Existing material weaknesses in internal control over financial reporting could adversely affect the ability to record, process, summarize, and report financial information.

Future Outlook

The company expects to continue incurring net losses and negative operating cash flows for the foreseeable future, necessitating additional funding through equity offerings and debt financings. Research and development expenses are anticipated to decrease in 2024 as the AUDACITY clinical trial nears completion. Management is committed to engaging with the French regulatory authority (ANSM) to resume commercialization in France and intends to monitor its common stock price to regain compliance with NYSE listing standards, having submitted a plan to the NYSE for market capitalization compliance within 18 months.

Management Comments

• "We intend to monitor the closing bid price of our Common Stock and may, if appropriate, consider available options to regain compliance with the NYSE minimum share price requirement."
• "We submitted a plan to the NYSE outlining measures designed to regain compliance with the continued listing standard within 18 months of receipt the written notice."
• "The Company is committed to continuing its engagement with ANSM to identify a path that will enable the Company to resume the commercialization of the Allurion Balloon in France."
• "We expect research and development expenses to continue to decrease in 2024 as our AUDACITY trial progresses toward completion."
• "Based on our recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and the potential need to raise additional capital to finance our future operations and debt service payments, we have concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that the consolidated financial statements included in this Quarterly Report on Form 10-Q/A are issued."

Industry Context

Allurion operates in the highly competitive and rapidly changing medical device industry, specifically targeting weight loss. The company faces competition from traditional pharmaceutical therapies, bariatric surgical treatments, and other intragastric balloons. Its Allurion Virtual Care Suite (VCS) is positioned to serve as a platform for long-term follow-up across various weight loss interventions, including anti-obesity medications and bariatric surgery, indicating a strategy to diversify and integrate with broader industry trends. A collaboration with Medtronic plc for VCS integration suggests leveraging strategic partnerships within the medical device sector.

Comparison to Industry Standards

• In commercial experience, the serious adverse event rate for the Allurion Balloon has been less than 0.2%, which is reported to be similar to the SAE profile in the literature.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• No accruals for probable losses related to any existing or pending litigation or claims as management has determined that there are no matters where a potential loss is probable and reasonably estimable.

Related Party Transactions

• Lease agreement for office space in Paris, France, with LNMP JPBC Invest (a related party), terminated in February 2024.
• Consulting agreements with KKG Enterprises, LLC and Remus Group Management, LLC (affiliated with director Krishna Gupta) for AI platform and advisory services, terminated on June 20, 2023.
• Convertible Note with Hunter Ventures Limited (HVL), affiliated with director Krishna Gupta, for $13 million of 2023 Convertible Notes.
• Consulting agreement with Benoit Chardon Consulting (BCC), solely owned by the company's former Chief Commercial Officer, terminated effective December 31, 2023.
• Convertible Note Agreement with RTW for $48.0 million, where RTW holds more than 5% of outstanding common stock and has board representation rights.
• RTW participated in the Public Offering, purchasing 9,594 shares of Common Stock and accompanying warrants for approximately $0.3 million.
• Private Placement with RTW for 2,260,159 shares of Series A Preferred Stock and 90,407 Private Placement Warrants for approximately $2.7 million.
• RTW elected to convert $7.5 million of its PIPE Investment into an additional Revenue Interest Financing Agreement (New RIFA) on October 22, 2024.

Stakeholder Impact

• Shareholders face significant risks including potential NYSE delisting, substantial dilution from future capital raises, and high stock price volatility. The reported net income improvement is largely non-operational.
• Employees are significantly impacted by the approved 50% workforce reduction (approximately 113 roles), leading to job losses and potential morale issues for remaining staff.
• Customers are affected by the suspension of Allurion Balloon sales in France, impacting product availability and potentially eroding trust. Decreased re-order rates indicate reduced demand.
• Creditors, particularly RTW, have significant influence through debt, preferred stock, and board representation. While the company is currently compliant with covenants, the 'going concern' warning raises long-term repayment concerns.
• Suppliers may experience reduced demand due to decreased production volumes and potential operational disruptions, impacting their business relationships with Allurion.

Next Steps

• Implement and complete a remediation plan to resume sales of the Allurion Balloon in France.
• Monitor common stock closing bid price and consider available options to regain compliance with the NYSE minimum share price requirement.
• Execute the plan submitted to the NYSE to regain compliance with the minimum market capitalization standard within 18 months.
• Obtain Stockholder Approval for the conversion of RTW Convertible Notes in excess of 1% of outstanding shares, calling special meetings if necessary.
• Complete the AUDACITY clinical trial and submit a premarket approval application to the FDA.
• Continue to raise additional capital through equity offerings and debt financings as needed to fund operations.
• Complete the majority of the restructuring plan in Q4 2024, with associated cash payments primarily in Q1 2025.
• Remediate material weaknesses in internal control over financial reporting by hiring additional accounting staff, implementing a new ERP system, establishing additional review controls, and utilizing external accounting firm assistance.

Key Dates

Recommendation

The company faces severe existential threats, including a 'going concern' warning, imminent NYSE delisting risk, and a 50% workforce reduction. The significant revenue decline and material weaknesses in financial controls indicate fundamental operational and governance issues. While net income improved, this was driven by non-operational fair value adjustments, not core business strength. The cumulative risks far outweigh any potential upside, making the stock a strong sell for investors.

Keywords

Allurion Technologies, ALUR, 10-Q/A, Restatement, Financials, Weight Loss, Intragastric Balloon, Medical Device, SEC Filing, Workforce Reduction, NYSE Delisting, Going Concern, RTW Convertible Notes, Revenue Interest Financing, Clinical Trials, AUDACITY, France Regulatory, Internal Controls, Corporate Governance, Capital Raise